BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22213870)

  • 1. [Initial therapy of imatinib mesylate for extramedullary T lymphoblastic crisis of chronic myeloid leukemia: a case report and review of the literature].
    He HS; Su GP; Chen BB
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):477-8. PubMed ID: 22213870
    [No Abstract]   [Full Text] [Related]  

  • 2. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
    Aftimos P; Nasr F
    Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
    [No Abstract]   [Full Text] [Related]  

  • 3. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
    Breccia M; Nanni M; Mancini F; Russo E; Mecarocci S; Alimena G
    Haematologica; 2004 Apr; 89(4):ECR11. PubMed ID: 15075103
    [No Abstract]   [Full Text] [Related]  

  • 4. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
    Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
    Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
    Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
    Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
    Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sudden blast crisis in a chronic myeloid leukemia patient during imatinib therapy.
    Voican I; Vlădăreanu AM; Bumbea H; Begu M
    Rom J Intern Med; 2012; 50(3):241-4. PubMed ID: 23330292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
    Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
    Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
    [No Abstract]   [Full Text] [Related]  

  • 13. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
    Fujisawa S; Yano K; Kobayashi M
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological fracture as a manifestation of extramedullary blastic crisis in chronic myelogenous leukemia: report of one case.
    Yu HH; Lu MY; Lin DT; Lin KH; Tang JL; Jou ST
    Acta Paediatr Taiwan; 2006; 47(3):150-4. PubMed ID: 17078470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
    Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
    J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
    [No Abstract]   [Full Text] [Related]  

  • 17. Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
    Breccia M; Santopietro M; Cannella L; Federico V; Loglisci G; Serrao A; Petrucci L; Salaroli A; Nanni M; De Propris MS; Diverio D; Alimena G
    Leuk Res; 2011 Jun; 35(6):e91-2. PubMed ID: 21316103
    [No Abstract]   [Full Text] [Related]  

  • 18. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
    Zonder JA; Schiffer CA
    Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
    Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
    Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.